LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article ; Online: The impact of enhanced recovery after gynaecological surgery: A systematic review and meta-analysis.

    O'Neill, Alice M / Calpin, Gavin G / Norris, Lucy / Beirne, James P

    Gynecologic oncology

    2022  Volume 168, Page(s) 8–16

    Abstract: Background: Enhanced Recovery After Surgery programs have become the gold standard of care in many surgical specialities.: Objectives: This updated systematic review and meta-analysis aims to evaluate how an ERAS program can impact outcomes across ... ...

    Abstract Background: Enhanced Recovery After Surgery programs have become the gold standard of care in many surgical specialities.
    Objectives: This updated systematic review and meta-analysis aims to evaluate how an ERAS program can impact outcomes across both benign and oncological gynaecological surgery to inform standard surgical practice.
    Search strategy: An electronic search of the SCOPUS, Embase and PubMed Medline databases was performed for relevant studies assessing the use of ERAS in patients undergoing gynaecological surgery compared with those without ERAS.
    Selection criteria: The studies included were all trials using ERAS programs in gynaecological surgery with a clearly outlined protocol which included at least four items from the most recent guidelines and recorded one primary outcome.
    Data collection and analysis: Meta-analysis was performed on two primary endpoints; post-operative length of stay and readmission rate and one secondary endpoint; rates of ileus. Further subgroup analyses was performed to compare benign and oncological surgeries.
    Main results: Forty studies (7885 patients) were included in the meta-analysis; 15 randomised controlled trials and 25 cohort studies. 21 studies (4333 patients) were included in meta-analyses of length of stay. Patients in the ERAS group (2351 patients) had a shortened length of stay by 1.22 days (95% CI: -1.59 - -0.86, P < 0.00001) compared to those in the control group (1982 patients). Evaluation of 27 studies (6051 patients) in meta-analysis of readmission rate demonstrated a 20% reduction in readmission rate (OR: 0.80, 95% CI: 0.65-0.97). Analysis of our secondary outcome, demonstrated a 47% reduction in rate of ileus compared to the control group.
    Conclusions: ERAS pathways significantly reduce length of stay without increasing readmission rates or rates of ileus across benign and oncological gynaecological surgery.
    MeSH term(s) Female ; Humans ; Postoperative Complications/epidemiology ; Gynecologic Surgical Procedures/adverse effects ; Gynecologic Surgical Procedures/methods ; Ileus/epidemiology ; Ileus/etiology ; Length of Stay ; Postoperative Period
    Language English
    Publishing date 2022-11-07
    Publishing country United States
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2022.10.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 885: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Endometrioid Adenocarcinoma Resembling Cutaneous Pilomatrix Carcinoma: A Case Report of an Aggressive Neoplasm in a Young Woman With Diffusely Aberrant Beta-catenin Expression and Associated Morular Metaplasia and Atypical Polypoid Adenomyoma-type Change.

    Keane, Ellen / Floyd, Ruairí / McDonnell, Caoimhe / Beirne, James P / Ó'Riain, Ciarán / Komanyane, Lore

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

    2023  Volume 42, Issue 5, Page(s) 466–471

    Abstract: Endometrioid carcinoma with histopathologic resemblance to cutaneous pilomatrix carcinoma with mutations in the gene encoding beta-catenin, CTNNB1 are rare. There are minimal numbers of reports of high-grade tumors with this divergent differentiation in ... ...

    Abstract Endometrioid carcinoma with histopathologic resemblance to cutaneous pilomatrix carcinoma with mutations in the gene encoding beta-catenin, CTNNB1 are rare. There are minimal numbers of reports of high-grade tumors with this divergent differentiation in the literature. We report the case of a 29-yr-old female with an unusual presentation of endometrial cancer with overall histologic appearance indicative of a recently reported aggressive subtype of Federation of Gynecology and Obstetrics (FIGO) IVB grade 3 endometrioid carcinoma with features resembling cutaneous pilomatrix carcinoma. She was treated with a primary chemotherapy regimen with an initial significant response to treatment before developing symptomatic brain metastasis for which she underwent whole-brain radiotherapy. We discuss the unusual histologic and radiologic presentation as well as her individual management throughout this case report. The apparent association with morular metaplasia and atypical polypoid adenomyoma suggests that this rare carcinoma is within a spectrum of lesions associated with aberrant beta-catenin expression/beta-catenin mutation. Its aggressive nature highlights the importance of early recognition of this rare lesion.
    MeSH term(s) Female ; Humans ; Pregnancy ; Adenomyoma/diagnosis ; Adenomyoma/genetics ; beta Catenin/genetics ; Bone Neoplasms ; Breast Neoplasms ; Carcinoma, Endometrioid/diagnosis ; Carcinoma, Endometrioid/genetics ; Adult
    Chemical Substances beta Catenin
    Language English
    Publishing date 2023-01-25
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 604859-6
    ISSN 1538-7151 ; 0277-1691
    ISSN (online) 1538-7151
    ISSN 0277-1691
    DOI 10.1097/PGP.0000000000000942
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1814: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes.

    Feeney, Laura / Harley, Ian Jg / McCluggage, W Glenn / Mullan, Paul B / Beirne, James P

    World journal of clinical oncology

    2020  Volume 11, Issue 11, Page(s) 868–889

    Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy in the western world. The majority of women presenting with the disease are asymptomatic and it has been dubbed the "silent killer". To date there is no effective minimally ... ...

    Abstract Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy in the western world. The majority of women presenting with the disease are asymptomatic and it has been dubbed the "silent killer". To date there is no effective minimally invasive method of stratifying those with the disease or screening for the disease in the general population. Recent molecular and pathological discoveries, along with the advancement of scientific technology, means there is a real possibility of having disease-specific liquid biopsies available within the clinical environment in the near future. In this review we discuss these discoveries, particularly in relation to the most common and aggressive form of EOC, and their role in making this possibility a reality.
    Language English
    Publishing date 2020-12-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2587357-X
    ISSN 2218-4333
    ISSN 2218-4333
    DOI 10.5306/wjco.v11.i11.868
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer

    Beirne, James P. / Gilmore, Alan / McInerney, Caitríona E. / Roddy, Aideen / Glenn McCluggage, W. / Harley, Ian J.G. / Abdullah Alvi, M. / Prise, Kevin M. / McArt, Darragh G. / Mullan, Paul B.

    Computational and Structural Biotechnology Journal. 2022 June 09,

    2022  

    Abstract: Cancers presenting at advanced stages inherently have poor prognosis. High grade serous carcinoma (HGSC) is the most common and aggressive form of tubo-ovarian cancer. Clinical tests to accurately diagnose and monitor this condition are lacking. Hence, ... ...

    Abstract Cancers presenting at advanced stages inherently have poor prognosis. High grade serous carcinoma (HGSC) is the most common and aggressive form of tubo-ovarian cancer. Clinical tests to accurately diagnose and monitor this condition are lacking. Hence, development of disease-specific tests are urgently required. The molecular profile of HGSC during disease progression was investigated in a unique patient cohort. A bespoke data browser was developed to analyse gene expression and DNA methylation datasets for biomarker discovery. The Ovarian Cancer Data Browser (OCDB) is built in C# with a .NET framework using an integrated development environment of Microsoft Visual Studio and fast access files (.faf). The graphical user interface is easy to navigate between four analytical modes (gene expression; methylation; combined gene expression and methylation data; methylation clusters), with a rapid query response time. A user should first define a disease progression trend for prioritising results. Single or multiomics data are then mined to identify probes, genes and methylation clusters that exhibit the desired trend. A unique scoring system based on the percentage change in expression/methylation between disease stages is used. Results are filtered and ranked using weighting and penalties. The OCDB’s utility for biomarker discovery is demonstrated with the identified target OSR2. Trends in OSR2 repression and hypermethylation with HGSC disease progression were confirmed in the browser samples and an independent cohort using bioassays. The OSR2 methylation biomarker could discriminate HGSC with high specificity (95%) and sensitivity (93.18%). The OCDB has been refined and validated to be an integral part of a unique biomarker discovery pipeline. It may also be used independently to aid identification of novel targets. It carries the potential to identify further biomarker assays that can reduce type I and II errors within clinical diagnostics.
    Keywords DNA methylation ; biomarkers ; biotechnology ; carcinoma ; computer software ; data collection ; diagnostic techniques ; disease progression ; gene expression ; multiomics ; ovarian neoplasms ; patients ; prognosis ; user interface
    Language English
    Dates of publication 2022-0609
    Publishing place Elsevier B.V.
    Document type Article
    Note Pre-press version
    ZDB-ID 2694435-2
    ISSN 2001-0370
    ISSN 2001-0370
    DOI 10.1016/j.csbj.2022.06.016
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Role of self-expanding metal stents in the management of variceal haemorrhage: Hype or hope?

    Hogan, Brian J / O'Beirne, James P

    World journal of gastrointestinal endoscopy

    2015  Volume 8, Issue 1, Page(s) 23–29

    Abstract: Despite the advances of medical, endoscopic and radiological therapy over recent years the mortality rates of acute variceal haemorrhage are still 16%-20% and the medium term outcome has not improved in the last 25 years. Early transjugular intrahepatic ... ...

    Abstract Despite the advances of medical, endoscopic and radiological therapy over recent years the mortality rates of acute variceal haemorrhage are still 16%-20% and the medium term outcome has not improved in the last 25 years. Early transjugular intrahepatic portosystemic shunt has proved to be an effective therapy for selected groups of patients with a high risk of re-bleeding and moderate liver disease. However, there is an unmet need for a therapy that can be applied in patients with a high risk of re-bleeding and advanced liver disease either as definitive therapy or as a bridge to permanent therapy. Self-expanding metal stents can be placed without the need for endoscopic or fluoroscopic control and, once in place, will provide effective haemostasis and allow a route for oral fluids and nutrition. They can remain in place whilst liver function recovers and secondary prophylaxis is initiated. We review the results of 6 case series including a total of 83 patients and the first randomised controlled trial of self-expanding metal stents vs balloon tamponade (BT) in the management of refractory variceal haemorrhage. We report that self-expanding metal stents provide effective haemostasis and perform better than BT in refractory bleeding, where they are associated with fewer complications. Whilst the most effective place for self-expanding metal stents in the management algorithm needs to be determined by further randomised controlled trials, currently they provide an effective alternative to BT in selected patients.
    Language English
    Publishing date 2015-09-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2573698-X
    ISSN 1948-5190
    ISSN 1948-5190
    DOI 10.4253/wjge.v8.i1.23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: A bespoke target selection tool to guide biomarker discovery in tubo-ovarian cancer.

    Beirne, James P / Gilmore, Alan / McInerney, Caitríona E / Roddy, Aideen / Glenn McCluggage, W / Harley, Ian J G / Abdullah Alvi, M / Prise, Kevin M / McArt, Darragh G / Mullan, Paul B

    Computational and structural biotechnology journal

    2022  Volume 20, Page(s) 3359–3371

    Abstract: Introduction: Cancers presenting at advanced stages inherently have poor prognosis. High grade serous carcinoma (HGSC) is the most common and aggressive form of tubo-ovarian cancer. Clinical tests to accurately diagnose and monitor this condition are ... ...

    Abstract Introduction: Cancers presenting at advanced stages inherently have poor prognosis. High grade serous carcinoma (HGSC) is the most common and aggressive form of tubo-ovarian cancer. Clinical tests to accurately diagnose and monitor this condition are lacking. Hence, development of disease-specific tests are urgently required.
    Methods: The molecular profile of HGSC during disease progression was investigated in a unique patient cohort. A bespoke data browser was developed to analyse gene expression and DNA methylation datasets for biomarker discovery. The Ovarian Cancer Data Browser (OCDB) is built in C# with a.NET framework using an integrated development environment of Microsoft Visual Studio and fast access files (.faf). The graphical user interface is easy to navigate between four analytical modes (gene expression; methylation; combined gene expression and methylation data; methylation clusters), with a rapid query response time. A user should first define a disease progression trend for prioritising results. Single or multiomics data are then mined to identify probes, genes and methylation clusters that exhibit the desired trend. A unique scoring system based on the percentage change in expression/methylation between disease stages is used. Results are filtered and ranked using weighting and penalties.
    Results: The OCDB's utility for biomarker discovery is demonstrated with the identified target OSR2. Trends in OSR2 repression and hypermethylation with HGSC disease progression were confirmed in the browser samples and an independent cohort using bioassays. The OSR2 methylation biomarker could discriminate HGSC with high specificity (95%) and sensitivity (93.18%).
    Conclusions: The OCDB has been refined and validated to be an integral part of a unique biomarker discovery pipeline. It may also be used independently to aid identification of novel targets. It carries the potential to identify further biomarker assays that can reduce type I and II errors within clinical diagnostics.
    Language English
    Publishing date 2022-06-17
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2694435-2
    ISSN 2001-0370
    ISSN 2001-0370
    DOI 10.1016/j.csbj.2022.06.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Epithelioid Trophoblastic Tumour: A Case with Genetic Linkage to a Child Born over Seventeen Years Prior, Successfully Treated with Surgery and Pembrolizumab.

    Pisani, David / Calleja-Agius, Jean / Di Fiore, Riccardo / O'Leary, John J / Beirne, James P / O'Toole, Sharon A / Felix, Ana / Said-Huntingford, Ian

    Current oncology (Toronto, Ont.)

    2021  Volume 28, Issue 6, Page(s) 5346–5355

    Abstract: Epithelioid trophoblastic tumours are rare neoplasms showing differentiation towards the chorion leave-type intermediate cytotrophoblast, with only a handful of cases being reported in the literature. These tumours are slow-growing and are typically ... ...

    Abstract Epithelioid trophoblastic tumours are rare neoplasms showing differentiation towards the chorion leave-type intermediate cytotrophoblast, with only a handful of cases being reported in the literature. These tumours are slow-growing and are typically confined to the uterus for extended periods of time. While the pathogenesis is unclear, they are thought to arise from a remnant intermediate trophoblast originating from prior normal pregnancies or, less frequently, gestational trophoblastic tumours. A protracted time period between the gestational event and tumour development is typical. This case describes a 49-year-old previously healthy female who presented with a completely asymptomatic uterine mass, discovered incidentally during a routine gynaecological assessment. The pathological analysis of the hysterectomy specimen confirmed an epithelioid trophoblastic tumour, involving the uterus and cervix. This is a rare gynaecological tumour. A comparative short tandem repeat analysis revealed genetic similarities to a previous healthy gestation seventeen years prior. She was successful treated with adjuvant pembrolizumab, with no evidence of disease recurrence to date.
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Female ; Genetic Linkage ; Gestational Trophoblastic Disease/drug therapy ; Gestational Trophoblastic Disease/genetics ; Gestational Trophoblastic Disease/surgery ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Pregnancy ; Uterine Neoplasms/drug therapy ; Uterine Neoplasms/genetics ; Uterine Neoplasms/surgery
    Chemical Substances Antibodies, Monoclonal, Humanized ; pembrolizumab (DPT0O3T46P)
    Language English
    Publishing date 2021-12-13
    Publishing country Switzerland
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1236972-x
    ISSN 1718-7729 ; 1198-0052
    ISSN (online) 1718-7729
    ISSN 1198-0052
    DOI 10.3390/curroncol28060446
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4305: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Vaginal Hysterectomy using the ERBE BiClamp

    Blayney, Gillian V / Beirne, James P / Hinds, Lynsey / Quinn, Declan / Dorman, Gary J

    The Ulster medical journal

    2017  Volume 86, Issue 3, Page(s) 167–171

    Abstract: ... The ERBE ... ...

    Abstract The ERBE BiClamp
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Analgesics/therapeutic use ; Blood Loss, Surgical ; Female ; Humans ; Hysterectomy, Vaginal/adverse effects ; Hysterectomy, Vaginal/instrumentation ; Hysterectomy, Vaginal/methods ; Length of Stay ; Middle Aged ; Operative Time ; Pain, Postoperative/drug therapy ; Reoperation ; Retrospective Studies ; Young Adult
    Chemical Substances Analgesics
    Language English
    Publishing date 2017-09-12
    Publishing country Northern Ireland
    Document type Journal Article
    ZDB-ID 603342-8
    ISSN 2046-4207 ; 0041-6193
    ISSN (online) 2046-4207
    ISSN 0041-6193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 217: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma.

    Byrne, Tara / Nelson, Laura / Beirne, James P / Sharpe, Daniel / Quinn, Jennifer E / McCluggage, W Glenn / Robson, Tracy / Furlong, Fiona

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2018  Volume 28, Issue 3, Page(s) 472–478

    Abstract: Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC).: ...

    Abstract Objectives: The aim of this study was to investigate the relationship between BRCA1 and mitotic arrest deficiency protein 2 (MAD2) protein expression, as determined by immunohistochemistry, and clinical outcomes in epithelial ovarian carcinoma (EOC).
    Methods: A tissue microarray consisting of 94 formalin-fixed paraffin-embedded EOC with fully matched clinicopathological data were immunohistochemically stained with anti-BRCA1 and anti-MAD2 antibodies. The cores were scored in a semiquantitative manner evaluating nuclear staining intensity and extent. Coexpression of BRCA1 and MAD2 was evaluated, and patient survival analyses were undertaken.
    Results: Coexpression of BRCA1 and MAD2 was assessed in 94 EOC samples, and survival analysis was performed on 65 high-grade serous carcinomas (HGSCs). There was a significant positive correlation between BRCA1 and MAD2 expression in this patient cohort (P < 0.0001). Both low BRCA1 and low MAD2 are independently associated with overall survival because of HGSC. Low coexpression of BRCA1 and MAD2 was also significantly associated with overall survival and was driven by BRCA1 expression.
    Conclusion: BRCA1 and MAD2 expressions are strongly correlated in EOC, but BRCA1 expression remains the stronger prognostic factor in HGSC.
    MeSH term(s) BRCA1 Protein/biosynthesis ; Biomarkers, Tumor/biosynthesis ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Female ; Humans ; Immunohistochemistry ; Mad2 Proteins/biosynthesis ; Middle Aged ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Paraffin Embedding ; Retrospective Studies ; Tissue Array Analysis
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human ; Biomarkers, Tumor ; MAD2L1 protein, human ; Mad2 Proteins
    Language English
    Publishing date 2018-02-21
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1097/IGC.0000000000001214
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3198: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma.

    Beirne, James P / McArt, Darragh G / James, Jacqueline A / Salto-Tellez, Manuel / Maxwell, Perry / McCluggage, W Glenn

    Histopathology

    2016  Volume 68, Issue 4, Page(s) 615–618

    MeSH term(s) Cystadenocarcinoma, Serous/metabolism ; Female ; Humans ; Ovarian Neoplasms/metabolism ; Retinoblastoma Protein/metabolism
    Chemical Substances Retinoblastoma Protein
    Language English
    Publishing date 2016-03
    Publishing country England
    Document type Comment ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 131914-0
    ISSN 1365-2559 ; 0309-0167
    ISSN (online) 1365-2559
    ISSN 0309-0167
    DOI 10.1111/his.12777
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1328: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top